Fundamentals Overview
ACADIA Pharmaceuticals Inc. is in the middle of its 52-week range with attractive valuation, trading relatively flat today.
Valuation attractive
Profitability
Risk (Beta)
0.83 — in line vol
Earnings & growth
BullzEye Analysis
Our composite tilts Hold on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.
Composite Signal
Supporting (Buy):
Analyst grade: B+ · Sentiment improving (2 upgrades)
Pressures (Sell):
3M vs S&P 500: -18.9% · 3M vs Healthcare sector: -12.1%
Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.
Key Stats
About
Ratings & Grades at a Glance
Overall rating: B+. Recent institutional grades: majority upgrades. Current institutional positions: Buy: 11, Hold: 2, Market Outperform: 3, Neutral: 3, Outperform: 5, Overweight: 4, Perform: 1, Sell: 1.
Valuation & Ratios
Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.
DCF vs price: DCF estimate is $-41.03; current price is $21.76. That’s a -288.6% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.
| Metric | Value |
|---|---|
| Valuation | |
| P/E (TTM) | 9.54 |
| PEG (TTM) | 0.13 |
| P/B (TTM) | 3 |
| P/S (TTM) | 3.46 |
| P/FCF (TTM) | 35.28 |
| Liquidity & enterprise | |
| Current Ratio (TTM) | 3.83 |
| Quick Ratio (TTM) | 3.71 |
| Cash Ratio (TTM) | 0.64 |
| Profitability | |
| ROE (TTM) | N/A |
| ROA (TTM) | N/A |
| Revenue growth (YoY) | N/A |
| Net margin (TTM) | 36.49% |
| Gross margin (TTM) | 91.69% |
| Operating margin (TTM) | 9.78% |
| Debt to equity (TTM) | N/A |
Latest News
News loads when you open this tab.
Price Target, Ratings & Grades
Analyst price targets, consensus, rating snapshot, and institutional grades for ACAD.
Analyst Sentiment at a Glance
Stock Grades (Institutions)
| Institution | Action | Previous Grade | New Grade | Date |
|---|---|---|---|---|
| B of A Securities | upgrade | Neutral | Buy | 2026-03-25 |
| JP Morgan | maintain | Overweight | Overweight | 2026-03-04 |
| Citizens | maintain | Market Outperform | Market Outperform | 2026-02-26 |
| TD Cowen | maintain | Buy | Buy | 2026-02-26 |
| Stifel | maintain | Hold | Hold | 2026-02-26 |
| RBC Capital | maintain | Outperform | Outperform | 2026-02-26 |
| Mizuho | upgrade | Neutral | Outperform | 2026-02-23 |
| Oppenheimer | maintain | Perform | Perform | 2026-02-06 |
| Citizens | maintain | Market Outperform | Market Outperform | 2026-02-03 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2026-02-03 |
| RBC Capital | maintain | Outperform | Outperform | 2026-02-03 |
| Citigroup | maintain | Buy | Buy | 2026-01-06 |
| UBS | maintain | Buy | Buy | 2026-01-06 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2025-12-15 |
| Stifel | maintain | Hold | Hold | 2025-12-11 |
| Mizuho | maintain | Neutral | Neutral | 2025-12-02 |
| JP Morgan | maintain | Overweight | Overweight | 2025-11-17 |
| RBC Capital | maintain | Outperform | Outperform | 2025-11-06 |
| Needham | maintain | Buy | Buy | 2025-11-06 |
| JP Morgan | maintain | Overweight | Overweight | 2025-09-29 |
| Needham | maintain | Buy | Buy | 2025-09-24 |
| TD Cowen | maintain | Buy | Buy | 2025-09-11 |
| UBS | maintain | Buy | Buy | 2025-09-09 |
| UBS | maintain | Buy | Buy | 2025-08-08 |
| RBC Capital | maintain | Outperform | Outperform | 2025-08-07 |
| B of A Securities | maintain | Neutral | Neutral | 2025-08-07 |
| Goldman Sachs | maintain | Sell | Sell | 2025-08-07 |
| JMP Securities | maintain | Market Outperform | Market Outperform | 2025-08-07 |
| Mizuho | maintain | Neutral | Neutral | 2025-08-07 |
| JP Morgan | maintain | Overweight | Overweight | 2025-07-24 |